Patent Cliff

What It Means

A patent cliff describes the steep, sudden decline in revenue that occurs when the patent on a high-revenue product expires and competitors enter the market with lower-priced alternatives. The term is most closely associated with the pharmaceutical industry, where branded drugs can lose 80-90% of their revenue within 12-18 months of generic entry. The word "cliff" captures the shape of the revenue chart: a long, flat plateau of protected sales followed by a near-vertical drop. The concept entered common use around 2011-2012 when Pfizer lost exclusivity on Lipitor (then generating $13 billion annually), and the industry simultaneously faced patent expirations on Plavix, Singulair, Seroquel, and other blockbusters. The current 2026-2030 patent cliff is the largest in pharmaceutical history, with drugs generating over $200 billion in combined annual revenue set to lose protection. Patent cliffs affect multiple stakeholders: pharmaceutical companies face existential revenue pressure that drives acquisition strategies, investors use expiration dates to model future cash flows, and patients benefit from dramatically lower generic prices. Companies attempt to mitigate patent cliffs through evergreening (filing continuation patents on new formulations), lifecycle management (launching line extensions), and litigation strategies (suing generic filers to trigger 30-month stays). PatentCliff tracks the expiration timelines of every major drug and technology patent, providing visibility into upcoming cliffs across the pharmaceutical and technology sectors.

Frequently Asked Questions